

TACTICAL COMBAT CASUALTY CARE COURSE

MODULE 15:
PAIN MEDICATIONS (ANALGESIA)



TCCC TIER 1 All Service Members

TCCC TIER 2 Combat Lifesaver **TCCC** TIER 3
Combat Medic/Corpsman

TCCC TIER 4
Combat Paramedic/Provider



TACTICAL COMBAT CASUALTY CARE (TCCC) ROLE-BASED TRAINING SPECTRUM

ROLE 1 CARE


NONMEDICAL PERSONNEL











YOU ARE HERE

STANDARDIZED JOINT CURRICULUM



1 x TERMINAL LEARNING OBJECTIVE

- Given a combat or noncombat scenario, perform analgesia administration during Tactical Field Care in accordance with CoTCCC Guidelines.
- **17.1** Identify the indications and considerations of analgesia approaches in Tactical Field Care.
- **17.2** Describe the indications, contraindications, dosage, route, and administration methods of oral acetaminophen in Tactical Field Care.
- Describe the indications, contraindications, dosage, route, and administration methods of oral meloxicam in Tactical Field Care.
- 17.4 Demonstrate the administration of a combat wound medication pack in Tactical Field Care.
- Describe the indications, contraindications, dosage, route, and administration methods of ondansetron in Tactical Field Care.
- Describe the indications, contraindications, dosage, route, and administration methods of oral transmucosal fentanyl citrate lozenges in Tactical Field Care.
- Demonstrate the preparation and administration of a transmucosal medication in Tactical Field Care.
- 17.8 Describe the indications, contraindications, dosage, route, and administration methods of fentanyl in Tactical Field Care.

16 x ENABLING LEARNING OBJECTIVES



1 x TERMINAL LEARNING OBJECTIVE

- Given a combat or noncombat scenario, perform analgesia administration during Tactical Field Care in accordance with CoTCCC Guidelines.
- Describe the indications, contraindications, dosage, route, and administration methods of ketamine in Tactical Field Care.
- 17.10 Describe the indications, contraindications, dosage, route, and administration methods of naloxone in Tactical Field Care.
- **17.11** Demonstrate the preparation and administration of an intranasal medication in Tactical Field Care.
- **17.12** Demonstrate the preparation and administration of an intramuscular medication injection in Tactical Field Care.
- 17.13 Demonstrate the preparation and administration of an intravenous/intraosseous medication injection in Tactical Field Care.
- **17.14** Identify the indications, considerations, and approaches to sedation in Tactical Field Care.
- 17.15 Demonstrate the preparation, administration, and management of procedural or analgesic sedation in Tactical Field Care.
- 17.16 Identify any evidence-based medicine, best practices, casualty data, and Subject Matter Expert consensus on the indications, contraindications, and administration methods of analgesia in Tactical Field Care.

16 x ENABLING LEARNING OBJECTIVES



MARCH PAWS

LIFE-THREATENING





RESPIRATION (Breathing)

CIRCULATION

HYPOTHERMIA /
HEAD INJURIES

AFTER LIFE-THREATENING








S SPLINTING



BATTLEFIELD ANALGESIA



Objectives of **PAIN MANAGEMENT**:


Reduce pain to a tolerable level while still protecting the casualty's airway and mentation

Allow casualties to return to the fight, when possible





APPROACH TO ANALGESIA IN TACTICAL FIELD CARE





Note: Routine use of morphine or benzodiazepines is NOT recommended for analgesia





ADMINISTRATION METHODS FOR PAIN MEDICATIONS

Route of Administration	Advantages	Disadvantages
Oral	Self-administration; no IV access needed	First-pass effect may reduce efficacy; delayed onset of action
Transmucosal	No IV access needed; rapid absorption	Requires casualty education on use; dose options may be limited
Intranasal (IN)	No IV access needed; rapid absorption	Impractical with nasal/facial trauma
Intramuscular (IM)	No IV access needed; may be absorbed slowly and have longer duration	Less predictable or incomplete dose delivery; delayed delivery with tissue perfusion compromise (shock)
Intravenous (IV)	Rapid (direct) medication delivery	IV access takes time; risk of overmedication; IV complication risks
Intraosseous (IO)	Rapid (direct) medication delivery	IO access takes time; risk of overmedication; IO complication risks

The **SIX RIGHTS**:

- RIGHT patient
- ✓ RIGHT medication
- RIGHT dose and concentration
- ✓ RIGHT time
- RIGHT route of administration
- ✓ RIGHT documentation





COMBAT WOUND MEDICATION PACK (CWMP)

The **CWMP** should be used by **all Service members** who are still able to fight with mild to moderate pain



Meloxicam

COX-2 inhibitor non-steroidal anti-inflammatory (NSAID)

15 mg tablet once a day



Acetaminophen

Two 500 mg tablets

Extra strength – up to 8 hours analgesia



DOD Trauma Registry study

Only 84 of 11,665 casualties took CWMP (<1%)

Emphasize to your unit that CWMP helps maintain tactical superiority and accomplish mission

No sedation or altered consciousness - casualty can stay engaged in the mission

CWMP should be self-administered, but might require prompt from **first** responders or medical personnel



Note: Aspirin and other NSAIDs cause platelet dysfunction for up to several days – do NOT use before/while deployed



Level of Evidence: C-LD





ACETAMINOPHEN ADMINISTRATION

DOSAGE(S):

500 mg, 2 PO every 8 hours

ROUTE(S):

Acetaminophen is available in PO form

INDICATIONS:

For **mild to moderate** pain management in a casualty that is still able to fight

CONTRAINDICATIONS:

Hypersensitivity

POTENTIAL SIDE EFFECTS:

Rash, nausea, vomiting, dizziness, lethargy, diaphoresis, chills or abdominal pain with acute poisoning, elevated LFTs, hypoglycemia and hepatorenal failure with hepatic toxicity



DRUG INTERACTIONS:

Cholestyramine may decrease absorption

Barbiturates, carbamazepine, phenytoin, rifampin, and excessive alcohol use may increase potential for hepatotoxicity

ONSET/PEAK/DURATION:

20-45 min/1-2 hr/3-4 hr

TACTICAL CONSIDERATIONS:

Minimal to no mission impact; DO NOT give to K-9 casualties





MELOXICAM ADMINISTRATION

DOSAGE(S):

15 mg tablet PO daily



ROUTE(S):

Meloxicam is available in PO form

INDICATIONS:

For **mild to moderate** pain management in a casualty that is still able to fight

CONTRAINDICATIONS:

NSAID or salicylate hypersensitivity, asthma, severe renal or hepatic disease

POTENTIAL SIDE EFFECTS:

Edema, flu-like syndrome, abdominal pain, diarrhea, dyspepsia, nausea, ulceration, Gl bleed, anemia, headache or insomnia

DRUG INTERACTIONS:

Decreased effect of ACE inhibitors and diuretics, increased lithium levels and toxicity, increased GI bleed risk with aspirin and warfarin

ONSET/PEAK/DURATION:

30-60 min/5-6 hr/20-24 hr

TACTICAL CONSIDERATIONS:


Minimal to no mission impact; DO NOT give to K-9 casualties







ORAL MEDICATION ADMINISTRATION



Video can be found on deployedmedicine.com



TRANSMUCOSAL MEDICATION ADMINISTRATION

ADVANTAGES

of transmucosal delivery:

- Rapid absorption (highly vascular tissues that are very permeable)
- Lack of first pass effect
- Can administer without IV or IO access or performing IM injection

 \triangle

Swallowing a transmucosal medication reduces its efficacy

Buccal mucosa vs. GI Tract

 \triangle

Do **NOT** allow casualty to eat or drink during administration

Oral transmucosal delivery options:

- Sublingual medication placed under the tongue where it dissolves
- **Transbuccal** medication held between cheek and gums

 Delivery enhanced by moving medication around or side-to-side
- **Translingual** medication applied or placed on the top of the tongue *Allow for dissolution and avoid swallowing until dissolved, as tolerated*









ONDANSETRON INDICATIONS AND ADMINISTRATION

Ondansetron **4 mg** oral disintegrating tablet (ODT) administration

- No need for IV or IO access
- Applied translingually by placing pill on top of tongue
- Advise the casualty NOT to swallow (don't take orally)



Ondansetron is also available in a parenteral form (IV, IM, or IO)

ADVANTAGES:

- Lack of sedation or mental status alteration
- No respiratory depression
- No hypotension

ADVERSE EFFECTS of other antiemetics:

- Sedation
- Respiratory depression
- Cognitive impairment







ONDANSETRON ADMINISTRATION

DOSAGE(S):

Ondansetron (ODT) **4 mg** q 8 hrs, repeat after 15 min for persistent symptoms, no more than 8 mg/8 hr time block

ONSET/PEAK/DURATION:

20 sec - 4 min (IV<IO<translingual<IM) / 10-40 min/4 hr

INDICATIONS:

Prevention and management of nausea and vomiting associated with pain management medications

CONTRAINDICATIONS:

Hypersensitivity

POTENTIAL SIDE EFFECTS:

Dizziness, lightheadedness, headache, sedation, diarrhea, constipation, dry mouth

TACTICAL CONSIDERATIONS:

Applied translingually by placing pill on top of tongue

Advise the casualty NOT to swallow (don't take orally)







FENTANYL INDICATIONS AND CONTRAINDICATIONS


INDICATIONS

Fentanyl is the medication of choice for a casualty in mild to moderate pain who **IS NOT** in shock or respiratory distress or at significant risk of developing either condition

CONTRAINDICATIONS

(applicable for all opioids):

- Hypovolemic shock
- Respiratory distress
- Unconsciousness
- Severe head injury



Ketamine should be used if one of these contraindications exist



TREATMENT END POINTS:

- Pain reduction (to tolerable level)
- No respiratory compromise, signs of shock or altered mentation

MANAGEMENT CONSIDERATIONS:

- Have naloxone ready to treat any overdose
- Disarm and remove comm equipment from casualties receiving fentanyl
- Assess mental status prior to fentanyl administration (AVPU)







Level of Evidence: A



ORAL TRANSMUCOSAL FENTANYL CITRATE (OTFC)

DOSAGE(S):

- First Dose 800 mcg of FENTANYL OTFC
- Second Dose may be repeated after 15 mins, if pain uncontrolled by first dose

ROUTE(S):

OTFC is administered transmucosally – place between the cheek and gum (Transbuccal)



Administering OTFC in a prehospital setting is an off-label use (not FDA approved), but consistent with expert panel recommendations

OTFC ADMINISTRATION:

Place between transbucally - cheek and gum

DO NOT chew or swallow

Tape lozenge-on-a-stick to casualty's finger OR attach to the casualty's uniform or plate carrier with a safety pin and rubber band

Reassess in 15 minutes

Use second lozenge, in other cheek, if pain is uncontrolled

Monitor for respiratory depression





Level of Evidence: A





OTFC ADMINISTRATION cont.


INDICATIONS:

Fentanyl is the medication of choice for a casualty in mild to moderate pain who IS NOT in shock or respiratory distress or at significant risk of developing either condition



CONTRAINDICATIONS:

- Hypovolemic shock
- Respiratory distress





Ketamine should be used if one of these contraindications exist

POTENTIAL SIDE EFFECTS:

Sedation, euphoria, bradycardia, hypotension, circulatory depression, miosis, blurred vision, nausea, vomiting, laryngospasm, bronchoconstriction or respiratory depression





OTFC ADMINISTRATION cont.

DRUG INTERACTIONS:

- Alcohol and other CNS depressants potentiate effects
- MAOIs may precipitate hypertensive crisis

ONSET/PEAK/DURATION:

15-60 sec (<transmucosal)/20 sec to 4 min/1-2 hr

TACTICAL CONSIDERATIONS:

- Casualty weapons, communications and sensitive equipment should be secured
- Alterations in mental status can adversely affect assessment for shock and/or traumatic brain injury





TREAMENT END POINTS:

- Pain reduction (to tolerable level)
- No respiratory compromise, signs of shock or altered mentation

ADVANTAGES:

- Rapid analgesia without an IV
- Saves time
- Low-light IV access difficult even with NVGs
- Safeguards resources for casualties who might need them

800 mcg of **FENTANYL** provided equivalent pain control to **10 mg** of **MORPHINE**





SKILL STATION

CWMP and Transmucosal Medication Administration



Combat Wound Medication Pack (CWMP)



Translingual Ondansetron Oral Disintegrating Tablet (ODT) Administration



Transbuccal OTFC Lozenge Administration



ADMINISTRATION OF FENTANYL

IN TACTICAL FIELD CARE

FENTANYL Routes of Administration




Oral transmucosal



Intranasal (IN)



Intravenous (IV)



Intraosseous (IO)

Parenteral FENTANYL Dosing in TFC

- 50 mcg (0.5-1 mcg/kg) IV/IO, may repeat q 30 min prn
- **100 mcg** IN, may repeat q 30 min prn

INDICATIONS:

Fentanyl is the medication of choice for a casualty in mild to moderate pain who IS NOT in shock or respiratory distress or at significant risk of developing either condition

ONSET/PEAK/DURATION:

- IV: Immediate/5-15mins/30-60min
- IN: 7mins/9-15mins/60mins

DRUG INTERACTIONS:

- Alcohol and other CNS depressants potentiate effects
- MAOIs may precipitate hypertensive crisis



FENTANYL ADMINISTRATION cont.

INTRANASAL ADVANTAGES:

- Rapid analgesia without an IV
- Saves time
- Low-light IV access difficult even with NVGs
- Safeguards resources for casualties who might need them

TREATMENT END POINTS:

- Pain control
- Hypotension/signs of shock, respiratory compromise

CONTRAINDICATIONS:

- Hypovolemic shock / Respiratory distress
- KETAMINE should be used if one of these contraindications exist

POTENTIAL SIDE EFFECTS:

 Sedation, euphoria, bradycardia, hypotension, circulatory depression, miosis, blurred vision, nausea, vomiting, laryngospasm, bronchoconstriction or respiratory depression

MANAGEMENT CONSIDERATIONS:

- Disarm and remove comm equipment
- Assess mental status prior to fentanyl administration (AVPU)
- Monitor airway and breathing
- Have naloxone ready to administer for suspected overdose







Level of Evidence: A





KETAMINE INDICATIONS AND CONTRAINDICATIONS



KETAMINE is the medication of choice for a casualty in moderate to severe pain and/or who **IS** in shock or respiratory distress or at significant risk of developing either condition

ADVANTAGES (compared to opioids):

- Equivalent pain relief
- Doesn't contribute to hypotension
- No respiratory depression
- Can safely be used as an adjunct to fentanyl

CONTRAINDICATIONS:

- Prior known allergy
- Not related to military population age under 3 or schizophrenia

SIDE EFFECTS:

- Well tolerated at analgesia doses
- Sedation, dissociation, or emergence reactions at higher doses used in anesthesia

KETAMINE can be safely used in head and eye injuries despite prior concerns over a potential increase ocular/cerebral pressures






KETAMINE ADMINISTRATION

IN TACTICAL FIELD CARE

KETAMINE Routes of Administration



Intranasal (IN) Intrami



Intramuscular (IM)

Intraosseous (IO)

KETAMINE Dosing in TFC

- **20-30 mg** (0.2-0.3 mg/kg) slow IV or IO push (over one minute), then repeat q 20 mins prn
- **50-100 mg** (0.5-1 mg/kg) IM or IN, then repeat q 20-30 mins prn

KETAMINE Dosing in long duration analgesia

0.3 mg/kg slow IV/IO infusion in 100mL 0.9% sodium chloride (over 5-15 mins), then q 45 min prn

MANAGEMENT CONSIDERATIONS:

- Disarm and remove comm equipment
- Assess mental status prior to ketamine administration (AVPU)
- Monitor airway and breathing







KETAMINE ADMINISTRATION cont.

POTENTIAL SIDE EFFECTS:

- Well tolerated at analgesia doses
- Sedation, dissociation, or emergence reactions at higher doses used in anesthesia

ADVERSE EFFECTS:

- Well tolerated at analgesia doses
 - Sedation, dissociation, or emergence reactions at higher doses used in anesthesia
- Nausea
- Headache

TREATMENT END POINTS:

- Pain control
- Nystagmus



DRUG INTERACTIONS:

Effects of ketamine are increased when combines with other analgesics or muscle relaxants

ONSET/PEAK/DURATION:

30 sec-4min (IV<IO<IN<IM)/1-10 min/5-25 min



used in head and eye injuries despite prior concerns over a potential increase ocular/cerebral pressures



ADMINISTRATION OF NALOXONE IN TACTICAL FIELD CARE

Naloxone is indicated in opioid overdoses

- Hypotension
- Respiratory depression or distress
- Excess alteration of mentation or unconsciousness

ROUTES OF ADMINISTRATION:

- Intranasal (IN)
- Intramuscular (IM)
- Intravenous (IV)
- Intraosseous (IO)



NALOXONE dosing in TFC:0.4 mg (IN, IM, IV, or IO)Repeat q 2-3 min until symptoms reverse or max dose of 10 mg

CONSIDERATIONS:

- Have naloxone on hand whenever administering opiates
- Administer as quickly as possible (don't delay for IV access to be established use IN or IM preparations)



Level of Evidence: B-R



NALOXONE ADMINISTRATION cont.

CONTRAINDICATIONS:

Hypersensitivity

POTENTIAL SIDE EFFECTS:

Analgesia reversal, tremors, hyperventilation, drowsiness, sweating, increased BP, tachycardia, nausea, and vomiting

DRUG INTERACTIONS:

Cardiotoxic drugs (may cause serious CV effects)

ONSET/PEAK/DURATION:

1-2 min/5-15 min/variable

TACTICAL CONSIDERATIONS:

Have naloxone on hand whenever administering opioid analgesics

Administer as quickly as possible (don't delay for IV access to be established with OTFC lozenges – use IN or IM preparations)





INTRANASAL MEDICATION ADMINISTRATION

ROUTES OF ADMINISTRATION:

- Check to ensure that the casualty has no known drug allergies to the medication(s) being administered (ask the casualty or locate their red allergy dog tag or bracelet).
- Gather necessary medication(s)
- Verify the five "rights"

Prepare for intranasal administration:

- Confirm nasal passages clear of obstructions (select least obstructed side)
- No blood or fluids present
- Have casualty blow nose, if possible

TCCC medications delivered by IN route: ketamine and naloxone; also, fentanyl



Unit-dosed pump sprays

- Set volume using plunger
- Spray tip atomizes to form mist




Individual-dose plungers or syringes

- Set volume
- Atomized mist from spray tip



INTRANASAL MEDICATION ADMINISTRATION



Video can be found on deployedmedicine.com



INTRAMUSCULAR MEDICATION ADMINISTRATION

INTRAMUSCULAR sites:

DELTOID

center of the deltoid muscle; 22-gauge, 1 inch needle

THIGH

halfway between knee and hip, lateral to the midline; 22-gauge, 1½ inch needle

BUTTOCK

Center of the upper, outer quadrant of the gluteal region; 22-gauge, 1½ inch needle

INJECTION CONSIDERATIONS:

- Inject air into medication vial before withdrawing to avoid negative pressure effects
- Ensure no air present in syringe and needle
- Insert needle with your dominant hand
- Press plunger fully to deliver full dose


If you encounter an auto-injector:

- Confirm dose
- Keep tight against skin
- Maintain in place for 10 sec after activation to ensure full delivery

TCCC pain medications delivered by IM route: ketamine, naloxone, and ondansetron



INTRAMUSCULAR MEDICATION ADMINISTRATION



Video can be found on deployedmedicine.com




INTRAVENOUS/INTRAOSSEOUS

MEDICATION ADMINISTRATION




IV saline locks

- Can use same needle from draw
- Flush to ensure med delivery and keep lock patent



IO extension sets

- Clamp extension set when cap open
- Use syringe without needle
- Flush like IV saline lock



IV tubing (using IV or IO access)

- Close clamps or pinch tubing above injection port during administration
- Flush with saline or LR


RATE OF INFUSION CONSIDERATIONS:

- Some medications must be pushed slowly
- Small volumes over long pushes are hard to manage consider dilution to have larger volume

TCCC Medications delivered by IV or IO route: ketamine, ondansetron, and naloxone; also, fentanyl and midazolam




INTRAVENOUS MEDICATION ADMINISTRATION



Video can be found on deployedmedicine.com



INTRAOSSEOUS MEDICATION ADMINISTRATION



Video can be found on deployedmedicine.com



SEDATION IN TFC: INDICATIONS, CONSIDERATIONS AND APPROACHES

INDICATION: – used when significant severe injuries require dissociation for patient safety or mission success or invasive procedures

EXAMPLES:

- During transport ease of administration
- When movements/spaces are restricted
- Critical interventions requiring analgesia
- Prolonged analgesia or evacuation
- When OPTEMPO dictates

APPROACHES:

- Initial ketamine dosing is 1-2 mg/kg slow IV push or 2-3 mg/kg (300 mg) IM
- End point is achievement of procedural (dissociative) anesthesia
- For continued sedation, follow JTS CPG guidance on Analgesia in Prolonged Field Care

CONSIDERATIONS:

- Sedation requires continuous monitoring (pulse ox or ETCO2/cardiac monitor)
- Airway monitoring and maintenance (casualty positioning, airway adjuncts, and/or advanced airway placement)



Treat emergence phenomenon with Midazolam 0.5-2 mg IV/IO/IM



Level of Evidence: B-R



ASSESSING THE EVIDENCE FOR GUIDELINES

Level of Evidence	AHA Recommendation System Terminology Explanation	Why the AHA Classification System?	
A	Evidence from multiple randomized clinical trials (RCT) with concordant results or from HIGH-QUALITY meta-analyses.	 The level of evidence recommendations allow readers to quickly glean information on the strength, certainty, and quality of evidence supporting each recommendation. A recommendation with Level of Evidence (LOE) C does not imply that the recommendation is weak. Although, RCTs are unavailable, 	
B-R	Evidence from moderate-quality trials, or a meta-analysis of moderate quality (RCT) followed by an R to denote RANDOMIZED studies		
B-NR	Evidence from moderate-quality trials, or a meta-analysis of moderate quality followed by NR to denote NON-RANDOMIZED studies		
C-LD	There is no convincing evidence and is followed by LD to indicate LIMITED DATA		
C-EO	There is no convincing evidence and is followed by EO if the consensus is based on EXPERT OPINION , case studies or standards of care.	there may be a very clear clinical consensus that a particular test or therapy is useful or effective.	





EVIDENCE SUPPORTING TCCC PAIN MEDICATION GUIDANCE

Subject Category	Study Types	Level of Evidence
Combat Wound Medication Pack	Meta-analysis of observational studies, lab evaluations and case studies	C-LD
Fentanyl (indications in TFC, dosages/routes)	Meta-analysis of multiple Randomized Controlled Trials	A
Ondansetron (indications in TFC, dosages/routes)	Prospective, Randomized, Double-blind, Placebo- Controlled Trial	A
Ketamine (indications in TFC, dosages/routes)	Randomized, Double-blind, Placebo-Controlled, Crossover trial and Prospective Randomized Study	B-R
Naloxone (indications in TFC, dosages/routes)	Meta-analysis from Multiple Randomized Controlled Trials	B-R
Sedation in Tactical Field Care	Meta-analysis from Multiple Randomized Controlled Trials	B-R



SKILL STATION

IN, IM, IV/IO Medication and Analgesic Sedation Administration



Intranasal Medication Administration



Intramuscular Medication Administration



Intravenous/Intraosseous Medication Administration



Analgesic Sedation Administration



SUMMARY

Knowledge Topics

- Indications and considerations of analgesia approaches
- Indications, contraindications, dosage, route, and administration methods of oral medication
- Indications, contraindications, dosage, route, and administration methods of transmucosal medication
- Indications, contraindications, dosage, route, and administration methods of IM/IN/IV/IO medication
- Indications, considerations, and approaches to sedation
- Identify evidence-based medicine on the indications, contraindications, and administration methods of analgesia in TFC

Skills and Abilities

- Oral Medication Preparation and Administration
- OTFC Medication Preparation and Administration
- IM/IN/IV/IO Medication Preparation and Administration
- Preparation, Administration and Management of procedural or analgesic sedation






CHECK ON LEARNING

- What are the contraindications of using the oral transmucosal fentanyl citrate (OTFC) lozenges for moderate to severe pain?
- Which CoTCCC-recommended analgesia medications can be given by the intranasal route?
- Why is it okay to take the meloxicam in the CWMP but not Motrin?
- What are the advantages of using ketamine instead of fentanyl for moderate to severe pain control in the face of shock or respiratory compromise?
- Name the three intramuscular injection sites and their landmarks












REFERENCES



TCCC: Guidelines

by JTS/CoTCCC

These guidelines, updated regularly, are the result of decisions made by CoTCCC in exploring evidence-based research on best practices.

PHTLS: Military Edition, Chapter 25 by NAEMT

Prehospital Trauma Life Support (PHTLS), Military Edition, teaches and reinforces the principles of rapidly assessing a trauma patient using an orderly approach.